Information Provided By: 
Fly News Breaks for May 6, 2015
ALXN
May 6, 2015 | 15:11 EDT
Cowen says Alexion (ALXN) remains a top pick and shares should be bought aggressively on weakness. The firm said the Synageva (GEVA) acquistion further expands Alexion's metabolic franchises and brings in a late stage blockbuster product candidate Kanuma, an enzyme replacement therapy for LAL-D, with U.S. and E.U. approvals.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
